A clinical approach to children with C3 glomerulopathy
| Autor: | Joshua M. Thurman, Marina Vivarelli, Raffaella Labbadia, Francesca Diomedi-Camassei, Nicole C. A. J. van de Kar |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male Nephrology medicine.medical_specialty Adolescent Glomerulonephritis Membranoproliferative 030232 urology & nephrology Disease 030204 cardiovascular system & hematology Nephropathy 03 medical and health sciences Glomerulonephritis 0302 clinical medicine Glomerulopathy Internal medicine Membranoproliferative glomerulonephritis medicine Humans Child Intensive care medicine business.industry medicine.disease Idiopathic Membranous Nephropathy Complement (complexity) Clinical trial Renal disorders Radboud Institute for Molecular Life Sciences [Radboudumc 11] Complement Inactivating Agents Pediatrics Perinatology and Child Health Female Kidney Diseases business |
| Zdroj: | Pediatric Nephrology, 37, 521-535 Pediatric Nephrology, 37, 3, pp. 521-535 |
| ISSN: | 1432-198X 0931-041X |
| Popis: | Item does not contain fulltext C3 glomerulopathy is a relatively new clinical entity that represents a challenge both to diagnose and to treat. As new therapeutic agents that act as complement inhibitors become available, many with an oral formulation, a better understanding of this disease and of the underlying complement dysregulation driving it has become increasingly useful to optimize patient care. Moreover, recent advances in research have clarified the role of complement in other glomerular diseases in which its role was less established, namely in immune-complex membranoproliferative glomerulonephritis (IC-MPGN), ANCA-vasculitis, IgA nephropathy, and idiopathic membranous nephropathy. Complement inhibitors are being studied in adult and adolescent clinical trials for these indications. This review summarizes current knowledge and future perspectives on every aspect of the diagnosis and management of C3 glomerulopathy and elucidates current understanding of the role of complement in this condition and in other glomerular diseases in children. An overview of ongoing trials involving therapeutic agents targeting complement in glomerular diseases is also provided. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink